Palvella Therapeutics (NASDAQ: PVLA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Palvella Therapeutics reported 63 open-market sales of 106,948 shares ($13.8m) and 3 open-market purchases of 6,845 shares ($849,974), by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Palvella Therapeutics shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
21 October 2026	Goin Kathleen	Chief Operating Officer	Option exercise, 10b5-1 plan	+2,165	$7.14	2,165	Form 4
21 October 2026	Goin Kathleen	Chief Operating Officer	Option exercise, 10b5-1 plan	+2,148	$9.08	4,313	Form 4
21 October 2026	Goin Kathleen	Chief Operating Officer	Open-market sale, 10b5-1 plan	−2,043	$123.62	2,270	Form 4
21 October 2026	Goin Kathleen	Chief Operating Officer	Open-market sale, 10b5-1 plan	−1,663	$125.16	607	Form 4
21 October 2026	Goin Kathleen	Chief Operating Officer	Open-market sale, 10b5-1 plan	−607	$126.19	0	Form 4
14 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−476	$121.14	139,314	Form 4
14 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−2,072	$122.62	137,242	Form 4
14 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−2,604	$123.29	134,638	Form 4
14 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−920	$124.37	133,718	Form 4
14 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−597	$125.33	133,121	Form 4
14 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−505	$126.55	132,616	Form 4
13 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−922	$133.72	139,790	Form 4
13 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−2,004	$128.52	144,960	Form 4
13 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−1,644	$129.23	143,316	Form 4
13 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−990	$130.48	142,326	Form 4
13 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−1,035	$131.49	141,291	Form 4
13 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−579	$132.40	140,712	Form 4
12 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−5,095	$132.62	155,021	Form 4
12 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−2,458	$133.25	152,563	Form 4
12 October 2026	Jenkins George M	Director	Open-market sale, 10b5-1 plan	−3,335	$134.21	149,228	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Palvella Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.